

NeuroSearch A/S  
Pederstrupvej 93  
DK - 2750 Ballerup  
Denmark  
Telephone: +45 4460 8000  
Telefax: +45 4460 8080  
ns@neurosearch.dk  
www.neurosearch.com  
CVR No: DK-12 54 61 06

## Announcement

### Report on ordinary general meeting held in NeuroSearch A/S

Pursuant to announcement, the ordinary general meeting of NeuroSearch A/S was held today, Wednesday 30 April 2008.

The chairman of the board of directors presented the oral report. The annual report 2008 and the board of directors' proposal to carry the 2007 result forward to next year were adopted by the shareholders.

CEO Asger Aamund, Attorney-At-Law Marianne Philip and Jørgen Buus Lassen resigned from the board of directors.

Dr. Anders Ullman and Dr. Gerard Van Odijk were elected as new members of the board of directors. The appointment of both takes effect immediately.

The new board of directors now consists of the following members:

President & CEO Thomas Hofman-Bang (chairman)  
CEO Allan Andersen  
President & CEO Torbjörn Bjerke  
EVP Anders Ullman  
Group V.P., President & CEO Gerard van Odijk  
Lars Siim Madsen (elected by the employees)  
Torben Skov (elected by the employees)  
Mads Peder Gersdorff Korsgaard (elected by the employees)

PricewaterhouseCoopers was re-elected as NeuroSearch's sole auditor.

The board of directors was given authorisation by the shareholders until the next general meeting to acquire own shares of a total sum of up to 10 per cent of the company's share capital.

The guidelines presented by the board of directors for incentive payments to the board of directors and the executive management, pursuant to Section 69b of the Danish Companies, paragraph 2, were adopted by the shareholders.

The following amendments to the Articles of Association were agreed upon by the shareholders with more than two third majority but could not be finally adopted as less than half of the share capital was represented at the ordinary general meeting: article 5 regarding an authorisation to the board of directors to increase the company's share capital and article 5a regarding an authorisation to the board of directors to issue warrants.

An extraordinary general meeting will therefore be held on 23 May 2008 at 11 am where the same amendments to the Articles of Association will be presented for adoption.

Thomas Hofman-Bang  
Chairman of the board of directors

**Contact persons:**

Flemming Pedersen, CEO, telephone: +45 2148 0118

Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,  
telephone: +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with GSK, ACR343 in Parkinson's disease (Phase I) and NSD-788 in anxiety a.o. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.